Jie Lou

Prof. Jie Lou


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJie Lou
Jie Lou
HDHongli Duan
Hongli Duan
QQQin Qin
Qin Qin
ZTZhipeng Teng
Zhipeng Teng
FGFengxu Gan
Fengxu Gan
XZXing Zhou
Xing Zhou
The oral route is the most preferred route for systemic and local drug delivery. However, the oral drug delivery system faces the harsh physiological and physicochemical environment of the gastrointestinal tract, which limits the bioavailability and targeted design of oral drug delivery system. Innovative pharmaceutical approaches including nanoparticulate formulations, biomimetic drug formulations, and microfabricated devices have been explored to optimize drug targeting and bioavailability. In this review, the anatomical factors, biochemical factors, and physiology factors that influence delivering drug via oral route are discussed and recent advance in conventional and novel oral drug delivery approaches for improving drug bioavailability and targeting ability are highlighted. We also address the challenges and opportunities of oral drug delivery systems in future.
1

10 January 2025 in Advanced Science
Verified
Journal Article
Open access
CZChengyuan Zhang
Chengyuan Zhang
YYYuchuan Yuan
Yuchuan Yuan
QXQiong Xia
Qiong Xia
JWJunjie Wang
Junjie Wang
KXKangkang Xu
Kangkang Xu
XZXing Zhou
Xing Zhou
Small molecules as nanomedicine carriers offer advantages in drug loading and preparation. Selecting effective small molecules for stable nanomedicines is challenging. This study used artificial intelligence (AI) to screen drug combinations for self‐assembling nanomedicines, employing physiochemical parameters to predict formation via machine learning. Non‐Steroidal Anti‐Inflammatory Drugs (NSAIDs) are identified as effective carriers for antineoplastic drugs, with high drug loading. Nanomedicines, PEG‐coated indomethacin/paclitaxel nanomedicine (PiPTX), and laminarin‐modified indomethacin/paclitaxel nanomedicine (LiDOX), are developed with extended circulation and active targeting functions. Indomethacin/paclitaxel nanomedicine iDOX exhibits pH‐responsive drug release in the tumor microenvironment. These nanomedicines enhance anti‐tumor effects and reduce side effects, offering a rapid approach to clinical nanomedicine development.

11 October 2025 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
GXGang Xiang
Gang Xiang
YCYuanxu Cui
Yuanxu Cui
PWPan Wang
Pan Wang
YFYuantao Feng
Yuantao Feng
CZChengyuan Zhang
Chengyuan Zhang
XZXing Zhou
Xing Zhou
Autoimmune diseases (ADs) arise from the breakdown of self-tolerance, leading to pathogenic immune responses against healthy tissues. The PD-1/PD-L1 immune checkpoint is pivotal for maintaining peripheral tolerance by suppressing autoreactive T cells, and its dysfunction drives the pathogenesis of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), and other ADs. Conventional approaches—including monoclonal antibodies, soluble PD-L1 fusion proteins, small-molecule or RNA regulators, and cell- or gene-based therapies—have shown promise. However, their broader application is constrained by systemic immunosuppression, off-target effects, infection and malignancy risks, and manufacturing complexities. Nanomedicine offers transformative solutions by leveraging polymeric nanoparticles, liposomes or lipid nanoparticles, extracellular vesicles (EVs), and biomimetic cell-membrane coatings to deliver PD-1/PD-L1 agonists with high spatial and temporal precision. These nanocarrier platforms enable localized checkpoint activation, co-delivery of tolerogenic agents, and improved biodistribution with reduced systemic toxicity. Here, we systematically review the structural and signaling features of the PD-1/PD-L1 axis, outlines the limitations of conventional therapeutic modalities, and highlights how nanocarrier-based approaches overcome these barriers to restore immune homeostasis in ADs. By integrating mechanistic insights with advanced delivery technologies, this review outlines a roadmap for next-generation, precision-engineered interventions aimed at reestablishing immune tolerance and improving clinical outcomes in ADs.

1 January 2020 in Theranostics
Verified
Journal Article
Open access
CXChunmei Xu
Chunmei Xu
LYLuqi Yin
Luqi Yin
ZTZhipeng Teng
Zhipeng Teng
XZXuemei Zhou
Xuemei Zhou
WLWenjie Li
Wenjie Li
XZXing Zhou
Xing Zhou
Rationale: The developement of oral targeted therapeutics for obesity and obesity-related diseases is challenging, as these diseases involve multiple lesions distributed throughout the whole body. Herein, we report a successful stragety for targeted oral delivery of bindarit to multiple obesity-related lesions including inflamed adipose tissue, fatty liver and atherosclerotic plaques.

22 May 2020 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
FWFang Wang
Fang Wang
ZTZhipeng Teng
Zhipeng Teng
Daohang LiuDaohang Liu
Daohang Liu
Yu-Chun WangYu-Chun Wang
Yu-Chun Wang
JLJie Lou
Jie Lou
ZDZhi Dong
Zhi Dong

Verified
Journal Article
Open access
PDF file
LXLijuan Xie
Lijuan Xie
FGFengxu Gan
Fengxu Gan
YHYun Hu
Yun Hu
YZYibin Zheng
Yibin Zheng
JLJunshan Lan
Junshan Lan
JLJie Lou
Jie Lou
Biomimetic nanodrug delivery systems based on cell membranes have emerged as a promising approach for targeted cancer therapy due to their biocompatibility and low immunogenicity. Among them, platelet-mediated systems are particularly noteworthy for their innate tumor-homing and cancer cell interaction capabilities. These systems utilize nanoparticles shielded and directed by platelet membrane coatings for efficient drug delivery. This review highlights the role of platelets in cancer therapy, summarizes the advancements in platelet-based drug delivery systems, and discusses their integration with other cancer treatments. Additionally, it addresses the limitations and challenges of platelet-mediated drug delivery, offering insights into future developments in this innovative field.